Design of Fab-based chimeric antibodies against <i>Bothrops asper</i> toxins by M. Haack, Aleksander et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 18, 2017
Design of Fab-based chimeric antibodies against Bothrops asper toxins
M. Haack, Aleksander; B. Hallgren, Malte; U. W. Friis, Rasmus; H. Dam, Søren; Martos Esteban, Andrea;
Andersen, Mikael Rørdam; Kilstrup, Mogens; Laustsen, Andreas Hougaard
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
M. Haack, A., B. Hallgren, M., U. W. Friis, R., H. Dam, S., Martos Esteban, A., Andersen, M. R., ... Laustsen, A.
H. (2016). Design of Fab-based chimeric antibodies against Bothrops asper toxins. Poster session presented at
Symposium for Biological and Life Science Students (SymBLS) 2016, Cambridge, United Kingdom.
D E P A R T M E N T   O F   B I O T E C H N O L O G Y   A N D   B I O M E D I C I N E   
T E C H N I C A L   U N I V E R S I T Y    O F   D E N M A R K 
 
 Design of Fab-based chimeric antibodies against Bothrops asper  toxins 
Aleksander M. Haack1,2, Malte B. Hallgren1,2, Rasmus U. W. Friis1,2,  Søren H. Dam1,2, Andrea Martos Esteban1, Mikael Rørdam Andersen1, Mogen Kilstrup1, Andreas  H. Laustsen1  1Department of Biotechnology and Biomedicine, Technical University of Denmark  2Department of Bio and Health Informatics, Technical University of Denmark 
Composition of B. asper  venom 
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Next steps: Determining the best antibody format 
Addressing the problem of immunogenic antivenoms 
Composition of B. asper venom[4] according to protein families, as percentages of the total protein content:  SVMPs: Snake Venom MetalloProteinase PLA2:  Phospholipases A2 CRISP:  Cysteine-Rich Secretory Proteins LAO:   L-amino Acid Oxidases SP:   Serine Proteinases DC:   Dendritic Cell Fragments 
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Construction of scFvBaP1 from a monoclonal antibody 
Results from the recombinant scFvBaP1 
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Transformation of antibody formats into E. coli 
Hybridoma cells secreting the monoclonal antibody against BaP1 (MABaP1) were made, and from these a recombinant single chain variable fragment (scFv) was constructed.  
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BaP1 Hybridoma cells 
B cells are harvested  Myeloma cells MABaP1 (monoclonal antibody) 
scFvBaP1 
Binding strength testing of chimeric antibodies by ELISA 
Binding strengths of the antibodies to BaP1 will be determined by ELISA. This will allow us to compare the different antibody formats in regards to how likely they are to neutralize BaP1. 
The scFvBaP1 was cloned into the pMST3 expression vector in frame with a SUMO (Small Ubiquitin-like Modifier) sequence. When subjected to SDS-PAGE, the sequenced SUMO-scFvBaP1 showed a band at 40 kDa as was predicted and SUMO protein around 13 kDa[5] (well 3 and 6 respectively). 
In vivo tests showed that scFvBaP1 specifically recognizes BaP1 and whole B. asper venom, and to a large extend neutralizes the main toxic effects of BaP1.  
Recombinant FabBaP1 and scFabBaP1 will be made from scFvBaP1. These are going to be expressed in Escherichia coli using a pUHE23-2 expression vector. The final protein model shown here is of the recombinant scFab.[6] 
pUHE23-2 
E. coli 
If good chimeric antibodies are obtained in good yield, the next steps will be to determine their KD and test the antibodies in a preclinical model. This will allow an in vivo  comparison between the different formats. 
Snakebite is one of the world’s most neglected tropical diseases, with an estimated 5 million bites per year, resulting in about 125.000 deaths.[1] The only current treatment for snakebite envenoming is antiserum derived from the blood of immunized mammals (typically horses).[2] These antisera are expensive to produce and carry a high risk of causing hyper-allergic reactions in human recipients due to their heterologous origin.[3] Here we report the discovery of chimeric scFvs against Bothrops asper  toxins. 
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Results presented here were obtained prior to the project[5] 
Results presented here were obtained prior to the project[5] 
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